MyCancerHaven for Patients & Caregivers
MyCancerHaven for Patients & Caregivers
  • 161
  • 6 301
Ravi Vij, in Discussion with Dr. Ken Shain M.D, PhD, On Personalized Therapy in Multiple Myeloma.
Ravi Vij, in Discussion with Dr. Ken Shain M.D, PhD, Co-Director, Pentecost Family Myeloma Research Center, Associate Member, Department of Malignant Hematology, Moffitt Cancer Cantre, Tampa, FL, On Personalized Therapy in Multiple Myeloma.
Переглядів: 6

Відео

Ravi Vij, in Discussion with Dr. Suresh Balasubramanian M.D, On Menin Inhibitors in Treatment of AML2:48Ravi Vij, in Discussion with Dr. Suresh Balasubramanian M.D, On Menin Inhibitors in Treatment of AML
Ravi Vij, in Discussion with Dr. Suresh Balasubramanian M.D, On Menin Inhibitors in Treatment of AML
Переглядів 1219 годин тому
Ravi Vij, in Discussion with Dr. Suresh Balasubramanian M.D, Assistant Professor, Department of Oncology, Karmanos Center Institute/Wayne State University School of Medicine, Detroit, MI, On Menin Inhibitors in Treatment of AML.
Ravi Vij, in Discussion with Dr. Deborah Stephens DO, On CLL: Outcomes in High-Risk Disease2:30Ravi Vij, in Discussion with Dr. Deborah Stephens DO, On CLL: Outcomes in High-Risk Disease
Ravi Vij, in Discussion with Dr. Deborah Stephens DO, On CLL: Outcomes in High-Risk Disease
Переглядів 1914 днів тому
Ravi Vij, in Discussion with Dr. Deborah Stephens DO, Associate Professor of Medicine, Division of Hematology and Hematologic Malignancies, Director of the Chronic Lymphocytic Leukemia and Ritcher's Program, Divsion of Hematology, University of North Carolina School of Medicine, On Chronic Lymphocytic Leukemia (CLL): Outcomes in High-Risk Disease
Ravi Vij, in Discussion with Dr. Douglas W Sborov MD on Update on Carvykti in Early Relapse of MM2:50Ravi Vij, in Discussion with Dr. Douglas W Sborov MD on Update on Carvykti in Early Relapse of MM
Ravi Vij, in Discussion with Dr. Douglas W Sborov MD on Update on Carvykti in Early Relapse of MM
Переглядів 1828 днів тому
Ravi Vij, in Discussion with Dr. Douglas W Sborov MD, Associate Professor of Medicine, Division of Hematology and Hematologic Malignancies, Director of the HCI Hematology Disease Center and Plasma Cell Dyscrasias (PCD) Program, University of Utah, On Update on Carvykti in Early Relapse of Multiple Myeloma
Ravi Vij, Discussing with Dr. Bita Fakhri MD On Treatment of Front-Line Chronic Lymphocytic Leukemia2:47Ravi Vij, Discussing with Dr. Bita Fakhri MD On Treatment of Front-Line Chronic Lymphocytic Leukemia
Ravi Vij, Discussing with Dr. Bita Fakhri MD On Treatment of Front-Line Chronic Lymphocytic Leukemia
Переглядів 34Місяць тому
Ravi Vij, in Discussion with Dr. Bita Fakhri MD, Assistant Professor of Medicine, Division of Hematology, Stanford University School of Medicine, On Treatment of Front-Line Chronic Lymphocytic Leukemia (CLL)
Ravi Vij, Discussing with Dr. Bita Fakhri MD On Treatment of Front-Line Chronic Lymphocytic Leukemia40:41Ravi Vij, Discussing with Dr. Bita Fakhri MD On Treatment of Front-Line Chronic Lymphocytic Leukemia
Ravi Vij, Discussing with Dr. Bita Fakhri MD On Treatment of Front-Line Chronic Lymphocytic Leukemia
Переглядів 23Місяць тому
Ravi Vij, in Discussion with Dr. Bita Fakhri MD, Assistant Professor of Medicine, Division of Hematology, Stanford University School of Medicine, On Treatment of Front-Line Chronic Lymphocytic Leukemia (CLL)
Ravi Vij, in Discussion with Dr. Ashraf Badros MD, On The Phase 3 AURIGA Study2:39Ravi Vij, in Discussion with Dr. Ashraf Badros MD, On The Phase 3 AURIGA Study
Ravi Vij, in Discussion with Dr. Ashraf Badros MD, On The Phase 3 AURIGA Study
Переглядів 26Місяць тому
Ravi Vij, in Discussion with Dr. Ashraf Badros MD, Professor of Medicine, Director of the Multiple Myeloma Service, University of Maryland School of Medicine, On The Phase 3 AURIGA Study
Ravi Vij, in Discussion with Dr. Ryan Jacobs MD, On Double Refractory CLL Treatment2:48Ravi Vij, in Discussion with Dr. Ryan Jacobs MD, On Double Refractory CLL Treatment
Ravi Vij, in Discussion with Dr. Ryan Jacobs MD, On Double Refractory CLL Treatment
Переглядів 36Місяць тому
Ravi Vij, in Discussion with Dr. Ryan Jacobs MD, Associate Professor of Internal Medicine, Atrium Health Levine Cancer Institute, Wake Forest University, North Carolina, On Treatment for Double Refractory Chronic Lymphocytic Leukemia (CLL)
Ravi Vij, in Discussion with Dr. Adam Kittai MD on The Chronic Lymphocytic Leukemia (CLL) Treatment2:38Ravi Vij, in Discussion with Dr. Adam Kittai MD on The Chronic Lymphocytic Leukemia (CLL) Treatment
Ravi Vij, in Discussion with Dr. Adam Kittai MD on The Chronic Lymphocytic Leukemia (CLL) Treatment
Переглядів 362 місяці тому
Ravi Vij, in Discussion with Dr. Adam Kittai MD, Associate Professor, CLL Clinical research leader. Icahn School of Medicine at Mount Sinai. New York, NY, On The Future of Treatment for Chronic Lymphocytic Leukemia (CLL) To get full access to this video: Join Us at www.mycancerheaven.org/ #leukemia
Ravi Vij, Discussing with Dr. Surbhi Sidana On Relapsed/Refractory Multiple Myeloma (RRMM) for RWE2:49Ravi Vij, Discussing with Dr. Surbhi Sidana On Relapsed/Refractory Multiple Myeloma (RRMM) for RWE
Ravi Vij, Discussing with Dr. Surbhi Sidana On Relapsed/Refractory Multiple Myeloma (RRMM) for RWE
Переглядів 352 місяці тому
Ravi Vij, in Discussion with Dr. Surbhi Sidana, Assistant Professor of Medicine. Blood and Marrow Transplantation & Ceklular Therapy, Stanford University School of Medicine, On Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience
Ravi Vij, in Discussion with Dr. Saad Z. Usmani, On The Phase 3 CEPHEUS Study2:07Ravi Vij, in Discussion with Dr. Saad Z. Usmani, On The Phase 3 CEPHEUS Study
Ravi Vij, in Discussion with Dr. Saad Z. Usmani, On The Phase 3 CEPHEUS Study
Переглядів 302 місяці тому
Ravi Vij, in Discussion with Dr. Saad Z. Usmani, Chief of Myeloma Service, Memorial Sloan Kettering Cancer Center, New York NY, On The Phase 3 CEPHEUS Study
Ravi Vij, in Discussion with Dr. Hua-Jay "Jeff" Cherng, MD On Approacing Front-Line Treatment DLBCL2:05Ravi Vij, in Discussion with Dr. Hua-Jay "Jeff" Cherng, MD On Approacing Front-Line Treatment DLBCL
Ravi Vij, in Discussion with Dr. Hua-Jay "Jeff" Cherng, MD On Approacing Front-Line Treatment DLBCL
Переглядів 232 місяці тому
Ravi Vij, in Discussion with Dr. Hua-Jay "Jeff" Cherng, MD, Assistant Professor of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, NewYork, NY: On Approacing Front-Line Treatment of DLBCL
Ravi Vij, in Discussion with Dr. Jay Yang MD On Approacing Front-Line Treatment of Unfit AMLPatients2:10Ravi Vij, in Discussion with Dr. Jay Yang MD On Approacing Front-Line Treatment of Unfit AMLPatients
Ravi Vij, in Discussion with Dr. Jay Yang MD On Approacing Front-Line Treatment of Unfit AMLPatients
Переглядів 242 місяці тому
Ravi Vij, in Discussion with Dr. Jay Yang MD, Associate Professor, Department of Oncology, Barbare Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI: On Approacing Front-Line Treatment of Unfit AML Patients
Ravi Vij, in Discussion with Dr. Anand A. Patel MD on Treating Newly Diagnosed AALL2:29Ravi Vij, in Discussion with Dr. Anand A. Patel MD on Treating Newly Diagnosed AALL
Ravi Vij, in Discussion with Dr. Anand A. Patel MD on Treating Newly Diagnosed AALL
Переглядів 373 місяці тому
Ravi Vij, in Discussion with Dr. Anand A. Patel MD, Assitant Professor of Medicine, Medical Director, Inpatient Leukemia Service, University of Chicago, Chicago, IL: On Treating Newly Diagnosed Adult Acute Lymphoblastic Leukemia
Ravi Vij, in Discussion with Dr. Marc S. Hoffmann MD, On Chronic Lymphocytic Leukemia(CLL) Treatment1:38Ravi Vij, in Discussion with Dr. Marc S. Hoffmann MD, On Chronic Lymphocytic Leukemia(CLL) Treatment
Ravi Vij, in Discussion with Dr. Marc S. Hoffmann MD, On Chronic Lymphocytic Leukemia(CLL) Treatment
Переглядів 343 місяці тому
Ravi Vij, in Discussion with Dr. Marc S. Hoffmann MD, On Chronic Lymphocytic Leukemia(CLL) Treatment
Ravi Vij, in Discussion with Dr. Abdulraheem Yacoub MD: On Treating Myelofibrosis2:43Ravi Vij, in Discussion with Dr. Abdulraheem Yacoub MD: On Treating Myelofibrosis
Ravi Vij, in Discussion with Dr. Abdulraheem Yacoub MD: On Treating Myelofibrosis
Переглядів 443 місяці тому
Ravi Vij, in Discussion with Dr. Abdulraheem Yacoub MD: On Treating Myelofibrosis
Ravi Vij in Discussion with Dr. Prithviraj Bose MD on Choosing Second Line Therapy for Myelofibrosis2:31Ravi Vij in Discussion with Dr. Prithviraj Bose MD on Choosing Second Line Therapy for Myelofibrosis
Ravi Vij in Discussion with Dr. Prithviraj Bose MD on Choosing Second Line Therapy for Myelofibrosis
Переглядів 333 місяці тому
Ravi Vij in Discussion with Dr. Prithviraj Bose MD on Choosing Second Line Therapy for Myelofibrosis
Ravi Vij, in Discussion with Dr. Joshua Zeidner MD on Asciminib for treating CML2:16Ravi Vij, in Discussion with Dr. Joshua Zeidner MD on Asciminib for treating CML
Ravi Vij, in Discussion with Dr. Joshua Zeidner MD on Asciminib for treating CML
Переглядів 434 місяці тому
Ravi Vij, in Discussion with Dr. Joshua Zeidner MD on Asciminib for treating CML
Ravi Vij, in Discussion with Dr. Nicholas Short MD on Incorporating Blincyto and Besponsa in ALL2:29Ravi Vij, in Discussion with Dr. Nicholas Short MD on Incorporating Blincyto and Besponsa in ALL
Ravi Vij, in Discussion with Dr. Nicholas Short MD on Incorporating Blincyto and Besponsa in ALL
Переглядів 304 місяці тому
Ravi Vij, in Discussion with Dr. Nicholas Short MD on Incorporating Blincyto and Besponsa in ALL
Ravi Vij, in Discussion with Dr. Danielle M Brander MD on Evolving Concepts in CLL Management: MRD2:26Ravi Vij, in Discussion with Dr. Danielle M Brander MD on Evolving Concepts in CLL Management: MRD
Ravi Vij, in Discussion with Dr. Danielle M Brander MD on Evolving Concepts in CLL Management: MRD
Переглядів 274 місяці тому
Ravi Vij, in Discussion with Dr. Danielle M Brander MD on Evolving Concepts in CLL Management: MRD
Ravi Vij, in Discussion with Dr. Forat Lutfi MD, on Lisocel for DLBCL and MCL1:54Ravi Vij, in Discussion with Dr. Forat Lutfi MD, on Lisocel for DLBCL and MCL
Ravi Vij, in Discussion with Dr. Forat Lutfi MD, on Lisocel for DLBCL and MCL
Переглядів 334 місяці тому
Ravi Vij, in Discussion with Dr. Forat Lutfi MD, on Lisocel for DLBCL and MCL
Ravi Vij, in Discussion with Dr. Adriana Rossi MD: on ISTUXIMAB For Transplant ineligible Patients2:00Ravi Vij, in Discussion with Dr. Adriana Rossi MD: on ISTUXIMAB For Transplant ineligible Patients
Ravi Vij, in Discussion with Dr. Adriana Rossi MD: on ISTUXIMAB For Transplant ineligible Patients
Переглядів 235 місяців тому
Ravi Vij, in Discussion with Dr. Adriana Rossi MD: on ISTUXIMAB For Transplant ineligible Patients
Ravi Vij, in Discussion with Dr. Guru Subramanian Guru Murthy MD MS, on #BPDCN2:19Ravi Vij, in Discussion with Dr. Guru Subramanian Guru Murthy MD MS, on #BPDCN
Ravi Vij, in Discussion with Dr. Guru Subramanian Guru Murthy MD MS, on #BPDCN
Переглядів 575 місяців тому
Ravi Vij, in Discussion with Dr. Guru Subramanian Guru Murthy MD MS, on #BPDCN
Multiple Myeloma: Ready for the Return of Belantamab Mafadotin?2:35Multiple Myeloma: Ready for the Return of Belantamab Mafadotin?
Multiple Myeloma: Ready for the Return of Belantamab Mafadotin?
Переглядів 435 місяців тому
Multiple Myeloma: Ready for the Return of Belantamab Mafadotin?
Ravi Vij, in Discussion with Dr. Nirav Shah MD, on CAR-T Cells for Chronic Lymphocytic Leukemia1:51Ravi Vij, in Discussion with Dr. Nirav Shah MD, on CAR-T Cells for Chronic Lymphocytic Leukemia
Ravi Vij, in Discussion with Dr. Nirav Shah MD, on CAR-T Cells for Chronic Lymphocytic Leukemia
Переглядів 435 місяців тому
Ravi Vij, in Discussion with Dr. Nirav Shah MD, on CAR-T Cells for Chronic Lymphocytic Leukemia
Ravi Vij, in Discussion with Dr. Sascha Alexander Tuchman, MD On Managing M-Myeloma In The Elderly2:47Ravi Vij, in Discussion with Dr. Sascha Alexander Tuchman, MD On Managing M-Myeloma In The Elderly
Ravi Vij, in Discussion with Dr. Sascha Alexander Tuchman, MD On Managing M-Myeloma In The Elderly
Переглядів 336 місяців тому
Ravi Vij, in Discussion with Dr. Sascha Alexander Tuchman, MD On Managing M-Myeloma In The Elderly
Ravi Vij in Discussion With Dr. Jesus Gonzalez Lugo, MD, on MDS: How He Intend to Use Imetellstat2:46Ravi Vij in Discussion With Dr. Jesus Gonzalez Lugo, MD, on MDS: How He Intend to Use Imetellstat
Ravi Vij in Discussion With Dr. Jesus Gonzalez Lugo, MD, on MDS: How He Intend to Use Imetellstat
Переглядів 466 місяців тому
Ravi Vij in Discussion With Dr. Jesus Gonzalez Lugo, MD, on MDS: How He Intend to Use Imetellstat
Ravi Vij in Discussion with Dr. Nitya Nathwani MD, on Choosing B/w CAR-Ts & Bispecific Antibodies2:41Ravi Vij in Discussion with Dr. Nitya Nathwani MD, on Choosing B/w CAR-Ts & Bispecific Antibodies
Ravi Vij in Discussion with Dr. Nitya Nathwani MD, on Choosing B/w CAR-Ts & Bispecific Antibodies
Переглядів 376 місяців тому
Ravi Vij in Discussion with Dr. Nitya Nathwani MD, on Choosing B/w CAR-Ts & Bispecific Antibodies
Ravi Vij in Discussion with Dr. Sanghee Hong, MD, on How She Decides on HSCT2:30Ravi Vij in Discussion with Dr. Sanghee Hong, MD, on How She Decides on HSCT
Ravi Vij in Discussion with Dr. Sanghee Hong, MD, on How She Decides on HSCT
Переглядів 167 місяців тому
Ravi Vij in Discussion with Dr. Sanghee Hong, MD, on How She Decides on HSCT
Ravi Vij in Discussion with Dr. Al-Ola A Abdallah, MD on Using CAR-T Cells Post 1st Relapse in MM2:23Ravi Vij in Discussion with Dr. Al-Ola A Abdallah, MD on Using CAR-T Cells Post 1st Relapse in MM
Ravi Vij in Discussion with Dr. Al-Ola A Abdallah, MD on Using CAR-T Cells Post 1st Relapse in MM
Переглядів 367 місяців тому
Ravi Vij in Discussion with Dr. Al-Ola A Abdallah, MD on Using CAR-T Cells Post 1st Relapse in MM

КОМЕНТАРІ

  • @DrkathyDavis
    @DrkathyDavis Місяць тому

    😊😊 oncology study progressive health.😊

  • @avolier
    @avolier 8 місяців тому

    Please mention her book "Understanding Multiple Myeloma". Every single patient needs her book. It's the Bible for understanding myeloma!

  • @MohammedAlam-e6s
    @MohammedAlam-e6s 11 місяців тому

    ❤AsCO